Jubilant Therapeutics, Inc.

Jubilant Pharmova subsidiary discloses Phase 1/2 clinical data for JBI-802, a dual LSD1/HDAC6 inhibitor, selected for oral presentation at the ASH Annual Meeting. Preliminary data from 8 patients show